Dysglycemia and Glucose Control During Sepsis

Clinics in Chest Medicine

Volumn 37, Issue 2, 2016, Pages 309-319

  Plummer, Mark P ^a,b   Deane, Adam M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Glycemic variability; Hyperglycemia; Hypoglycemia; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; FLUDROCORTISONE; GLUCOSE; HEMOGLOBIN A1C; HETASTARCH; HYDROCORTISONE; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; BIOLOGICAL MARKER;

CRITICAL ILLNESS; DIABETES MELLITUS; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; STRESS HYPERGLYCEMIA; BLOOD; COMPLICATION;

BIOMARKERS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN; SEPSIS;

EID: 84959294104     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2016.01.010     Document Type: Review

References (74)

1. Brunkhorst F.M., Engel C., Bloos F., et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358(2):125-139.
2. Krinsley J.S., Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007, 35(10):2262-2267.
3. Krinsley J.S., Egi M., Kiss A., et al. Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Crit Care 2013, 17(2):R37.
4. Waeschle R.M., Moerer O., Hilgers R., et al. The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability. Crit Care 2008, 12(5):R129.
5. Ali N.A., O'Brien J.M., Dungan K., et al. Glucose variability and mortality in patients with sepsis. Crit Care Med 2008, 36(8):2316-2321.
6. Leonidou L., Michalaki M., Leonardou A., et al. Stress-induced hyperglycemia in patients with severe sepsis: a compromising factor for survival. Am J Med Sci 2008, 336(6):467-471.
7. Rady M.Y., Johnson D.J., Patel B.M., et al. Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc 2005, 80(12):1558-1567.
8. Egi M., Bellomo R., Stachowski E., et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med 2008, 36(8):2249-2255.
9. Egi M., Bellomo R., Stachowski E., et al. The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes. Crit Care Med 2011, 39(1):105-111.
10. Plummer M.P., Bellomo R., Cousins C.E., et al. Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. Intensive Care Med 2014, 40(7):973-980.
11. Clement S., Braithwaite S.S., Magee M.F., American Diabetes Association Diabetes in Hospitals Writing Committee, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004, 27(2):553-591.
12. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2007, 30(Suppl 1):S42-S47.
13. Marik P.E., Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004, 30(5):748-756.
14. Petit F., Bagby G.J., Lang C.H. Tumor necrosis factor mediates zymosan-induced increase in glucose flux and insulin resistance. Am J Physiol 1995, 268(2 Pt 1):E219-E228.
15. Siegel J.H., Cerra F.B., Coleman B., et al. Physiological and metabolic correlations in human sepsis. Invited commentary. Surgery 1979, 86(2):163-193.
16. Mizock B.A. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001, 15(4):533-551.
17. Lang C.H., Dobrescu C., Meszaros K. Insulin-mediated glucose uptake by individual tissues during sepsis. Metab Clin Exp 1990, 39(10):1096-1107.
18. Dimitriadis G., Leighton B., Parry-Billings M., et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 1997, 321(Pt 3):707-712.
19. Chiasson J.L., Shikama H., Chu D.T., et al. Inhibitory effect of epinephrine on insulin-stimulated glucose uptake by rat skeletal muscle. J Clin Invest 1981, 68(3):706-713.
20. Smith T.R., Elmendorf J.S., David T.S., et al. Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am J Physiol 1997, 272(6 Pt 1):E1071-E1079.
21. Hotamisligil G.S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271(5249):665-668.
22. Stegenga M.E., Vincent J.L., Vail G.M., et al. Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 2010, 38(2):539-545.
23. Esper A.M., Moss M., Martin G.S. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care 2009, 13(1):R18.
24. Kaukonen K.M., Bailey M., Egi M., et al. Stress hyperlactatemia modifies the relationship between stress hyperglycemia and outcome: a retrospective observational study. Crit Care Med 2014, 42(6):1379-1385.
25. Yu W.K., Li W.Q., Li N., et al. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counter-regulatory hormone concentrations. World J Gastroenterol 2003, 9(8):1824-1827.
26. Rao A.K., Chouhan V., Chen X., et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999, 48(5):1156-1161.
27. Giugliano D., Marfella R., Coppola L., et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997, 95(7):1783-1790.
28. Turina M., Fry D.E., Polk H.C. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med 2005, 33(7):1624-1633.
29. Shah B.R., Hux J.E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003, 26(2):510-513.
30. Laupland K.B., Gregson D.B., Zygun D.A., et al. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004, 32(4):992-997.
31. Vincent J.L., Preiser J.C., Sprung C.L., et al. Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care 2010, 14(1):R12.
32. Dungan K.M., Braithwaite S.S., Preiser J.C. Stress hyperglycaemia. Lancet 2009, 373(9677):1798-1807.
33. Van den Berghe G., Wilmer A., Milants I., et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006, 55(11):3151-3159.
34. Falciglia M., Freyberg R.W., Almenoff P.L., et al. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009, 37(12):3001-3009.
35. Frank J.A., Nuckton T.J., Matthay M.A. Diabetes mellitus: a negative predictor for the development of acute respiratory distress syndrome from septic shock. Crit Care Med 2000, 28(7):2645-2646.
36. Kar P., Jones K.L., Horowitz M., et al. Management of critically ill patients with type 2 diabetes: the need for personalised therapy. World J Diabetes 2015, 6(5):693-706.
37. Christiansen C., Johansen M., Christensen S., et al. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit Care 2013, 17(5):R192.
38. Tsoyi K., Jang H.J., Nizamutdinova I.T., et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 2011, 162(7):1498-1508.
39. Zmijewski J.W., Lorne E., Zhao X., et al. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 2008, 178(2):168-179.
40. Duncan A.I., Koch C.G., Xu M., et al. Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. Anesth Analg 2007, 104(1):42-50.
41. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
42. Ansari G., Mojtahedzadeh M., Kajbaf F., et al. How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther 2008, 25(7):681-702.
43. Gribble F.M., Ashcroft F.M. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000, 49(10 Suppl 2):3-6.
44. Landry D.W., Oliver J.A. The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345(8):588-595.
45. Gardiner S.M., Kemp P.A., March J.E., et al. Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide. Br J Pharmacol 1999, 128(8):1772-1778.
46. Vanelli G., Hussain S.N., Aguggini G. Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol 1995, 80(1):167-170.
47. Vanelli G., Hussain S.N., Dimori M., et al. Cardiovascular responses to glibenclamide during endotoxaemia in the pig. Vet Res Commun 1997, 21(3):187-200.
48. Warrillow S., Egi M., Bellomo R. Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 2006, 34(4):980-985.
49. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32(7):1327-1334.
50. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345(19):1359-1367.
51. COIITSS Study Investigators, Annane D., Cariou A., et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010, 303(4):341-348.
52. NICE-SUGAR Study Investigators, Finfer S., Liu B., et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012, 367(12):1108-1118.
53. Egi M., Bellomo R., Stachowski E., et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc 2010, 85(3):217-224.
54. Krinsley J.S., Schultz M.J., Spronk P.E., et al. Mild hypoglycemia is independently associated with increased mortality in the critically ill. Crit Care 2011, 15(4):R173.
55. Duning T., van den Heuvel I., Dickmann A., et al. Hypoglycemia aggravates critical illness-induced neurocognitive dysfunction. Diabetes Care 2010, 33(3):639-644.
56. Deane A.M., Horowitz M. Dysglycaemia in the critically ill - significance and management. Diabetes Obes Metab 2013, 15(9):792-801.
57. Mackenzie I.M., Whitehouse T., Nightingale P.G. The metrics of glycaemic control in critical care. Intensive Care Med 2011, 37(3):435-443.
58. Krinsley J.S. Glycemic variability and mortality in critically ill patients: the impact of diabetes. J Diabetes Sci Technol 2009, 3(6):1292-1301.
59. Lanspa M.J., Dickerson J., Morris A.H., et al. Coefficient of glucose variation is independently associated with mortality in critically ill patients receiving intravenous insulin. Crit Care 2014, 18(2):R86.
60. Quagliaro L., Piconi L., Assaloni R., et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52(11):2795-2804.
61. Ceriello A., Esposito K., Piconi L., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57(5):1349-1354.
62. Finfer S. Clinical controversies in the management of critically ill patients with severe sepsis: resuscitation fluids and glucose control. Virulence 2014, 5(1):200-205.
63. Bellomo R., Egi M. Glycemic control in the intensive care unit: why we should wait for NICE-SUGAR. Mayo Clin Proc 2005, 80(12):1546-1548.
64. Devos P., Preiser J.C. Tight blood glucose control: a recommendation applicable to any critically ill patient?. Crit Care 2004, 8(6):427-429.
65. Van den Berghe G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354(5):449-461.
66. Meyfroidt G., Keenan D.M., Wang X., et al. Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality. Crit Care Med 2010, 38(4):1021-1029.
67. NICE-SUGAR Study Investigators, Finfer S., Chittock D.R., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360(13):1283-1297.
68. Arabi Y.M., Dabbagh O.C., Tamim H.M., et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med 2008, 36(12):3190-3197.
69. De La Rosa Gdel C., Donado J.H., Restrepo A.H., et al. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care 2008, 12(5):R120.
70. Preiser J.C., Devos P., Ruiz-Santana S., et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009, 35(10):1738-1748.
71. Dellinger R.P., Levy M.M., Rhodes A., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41(2):580-637.
72. Ellger B., Westphal M., Stubbe H.D., et al. Glycemic control in sepsis and septic shock: friend or foe?. Anaesthesist 2008, 57(1):43-48. [in German].
73. Iapichino G., Albicini M., Umbrello M., et al. Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients. Intensive Care Med 2008, 34(10):1843-1850.
74. Savioli M., Cugno M., Polli F., et al. Tight glycemic control may favor fibrinolysis in patients with sepsis. Crit Care Med 2009, 37(2):424-431.